336 related articles for article (PubMed ID: 28902952)
21. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.
Casseres RG; Kahn JS; Her MJ; Rosmarin D
J Am Acad Dermatol; 2019 Jul; 81(1):265-267. PubMed ID: 30562567
[No Abstract] [Full Text] [Related]
22. Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report.
Tekin B; Salman A; Ergun T
Indian J Dermatol Venereol Leprol; 2017; 83(5):615-617. PubMed ID: 28731016
[No Abstract] [Full Text] [Related]
23. [Hidradenitis suppurativa treated with infliximab].
Obadia DL; Daxbacher EL; Jeunon T; Gripp AC
An Bras Dermatol; 2009; 84(6):695-7. PubMed ID: 20191188
[TBL] [Abstract][Full Text] [Related]
24. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
25. Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa.
Baerveldt EM; Kappen JH; Thio HB; van Laar JA; van Hagen PM; Prens EP
Ann Rheum Dis; 2013 Apr; 72(4):626-7. PubMed ID: 23148307
[No Abstract] [Full Text] [Related]
26. Hidradenitis suppurativa outcome measures and treatment goals.
Ingram JR
Br J Dermatol; 2014 Dec; 171(6):1293-4. PubMed ID: 25523257
[No Abstract] [Full Text] [Related]
27. A case of hidradenitis suppurativa refractory to anti-TNFalpha therapy in a patient with Crohn's disease.
Koilakou S; Karapiperis D; Tzathas C
Am J Gastroenterol; 2010 Jan; 105(1):231-2. PubMed ID: 20054324
[No Abstract] [Full Text] [Related]
28. Moderate to severe hidradenitis suppurativa treated with biological therapies.
Chinniah N; Cains GD
Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
[TBL] [Abstract][Full Text] [Related]
29. Pain in Hidradenitis Suppurativa: A Pilot Study.
Ring HC; Sørensen H; Miller IM; List EK; Saunte DM; Jemec GB
Acta Derm Venereol; 2016 May; 96(4):554-6. PubMed ID: 26631388
[No Abstract] [Full Text] [Related]
30. Guselkumab in the treatment of severe hidradenitis suppurativa.
Kovacs M; Podda M
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e140-e141. PubMed ID: 30480844
[No Abstract] [Full Text] [Related]
31. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
Arenbergerova M; Gkalpakiotis S; Arenberger P
Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial.
Pelekanou A; Kanni T; Savva A; Mouktaroudi M; Raftogiannis M; Kotsaki A; Giamarellos-Bourboulis EJ
Exp Dermatol; 2010 Jun; 19(6):538-40. PubMed ID: 19758320
[TBL] [Abstract][Full Text] [Related]
33. Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report.
Gutierrez E; Issa N; Resnik B
J Drugs Dermatol; 2022 Dec; 21(12):1358-1360. PubMed ID: 36468954
[TBL] [Abstract][Full Text] [Related]
34. Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A.
Bianchi L; Hansel K; Stingeni L
J Am Acad Dermatol; 2012 Dec; 67(6):e278-9. PubMed ID: 23158638
[No Abstract] [Full Text] [Related]
35. Management of patients with hidradenitis suppurativa.
Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
[TBL] [Abstract][Full Text] [Related]
36. Long-term therapy with anakinra in hidradenitis suppurativa in three patients.
André R; Marescassier H; Gabay C; Pittet B; Laffitte E
Int J Dermatol; 2019 Nov; 58(11):e208-e209. PubMed ID: 31353451
[No Abstract] [Full Text] [Related]
37. Severe hidradenitis suppurativa successfully treated with secukinumab.
Głowaczewska A; Szepietowski JC; Matusiak Ł
Dermatol Ther; 2020 Nov; 33(6):e13845. PubMed ID: 32544258
[No Abstract] [Full Text] [Related]
38. Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.
Nikolakis G; Kreibich K; Vaiopoulos A; Kaleta K; Talas J; Becker M; Zouboulis CC
F1000Res; 2021; 10():381. PubMed ID: 34540202
[TBL] [Abstract][Full Text] [Related]
39. Patients with a familial predisposition to hidradenitis suppurativa have a distinct clinical phenotype.
Jørgensen AR; Brøgger-Mikkelsen M; Ring HC; Thomsen SF
J Am Acad Dermatol; 2020 Dec; 83(6):1809-1811. PubMed ID: 32289402
[No Abstract] [Full Text] [Related]
40. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
Moul DK; Korman NJ
Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
